Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Presumed Central Serous Retinopathy Due to Sertraline (Sertraline Retinopathy)

Muhtemel Sertraline Bağlı Santral Seroz Retinopati

Pages
269–271
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Inconclussion, the patients who use sertralin should be aware of thepotential risk of developing CSR or the other macular changes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 36 year-old male patient who developed central serous retinop-athy (CSR) presumed to result from intake of sertraline hydro-chloride (100 mg per day) during one year.A complete ocular examination, color vision testing, automatedstatic perimetry, optical coherence tomography (OCT) and fun-dus fl uorescein angiography (FFA) were performed.
📊
Key Findings & Data:OCT andFFA fi ndings were revealed a central serous retinopathy in theright eye in a patient who use sertraline for more than a year.
💡
Conclusion & Impact:Inconclussion, the patients who use sertralin should be aware of thepotential risk of developing CSR or the other macular changes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 36 year-old male patient who developed central serous retinop-athy (CSR) presumed to result from intake of sertraline hydro-chloride (100 mg per day) during one year.A complete ocular examination, color vision testing, automatedstatic perimetry, optical coherence tomography (OCT) and fun-dus fl uorescein angiography (FFA) were performed. OCT andFFA fi ndings were revealed a central serous retinopathy in theright eye in a patient who use sertraline for more than a year. Inconclussion, the patients who use sertralin should be aware of thepotential risk of developing CSR or the other macular changes.

🔖

Cite This Article

DOĞANAY, S., ÇAVDAR, M., NURLU, K., CUMURCU, T., CUMURCU, B. E., ZAYMAN, E. P. (2022). Presumed Central Serous Retinopathy Due to Sertraline (Sertraline Retinopathy). Retina-Vitreus, Cilt: 26 - Sayı: 0, 269–271. https://ajindex.com/articles/589136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Budavari S (1989): The Merck Index, 11th edition. p 1342. Rah- way, Merck and Co. Inc, Carrasco JL, Sandner C. Clinical eff ects of pharmacological vari- ations in selective serotonin reuptake inhibitors: an overview. Int J CIin Pract 2005; 59: 1428-1434.
  2. Dewan MJ, Anand VS. Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis. 1999; 187: 96-101. Sener EC and Kiratli H. Presumed sertraline maculopathy. Acta Ophthalmol Scand 2001: 79: 428–430. Mason JO 3rd and Patel SA. Bull’S eye maculopathy in a patient taking sertraline. Retin Cases Brief Rep. 2015; 9(2):131-3. Barret J. Anisocoria associated with selective serotonin reuptake inhibitors. Br Med J 1994; 309: 1620. Bourgeois JA, Thomas D, Johansen T, Walker DM. Visual hallu- cinations associated with fl uoxetine and sertraline. J Clin Psy- chopharmacol 1998; 18: 482–483. Lehman NL and Johnson LN. Toxic optic neuropathy after con- comitant use of melatonin, zoloft and a high-protein diet. J Neu- ro-Ophthalmol 1999; 19: 232–234.
  3. Van Cann EM, Koole R. Retrobulbar hematoma associated with selective serotonin reuptake inhibitor: a case report.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108: 1-2.